The important role of R&D in addressing AMR for better cancer care
How can Research and Development (R&D) for novel antimicrobial medicines and a secure access pipeline effectively address AMR?
On 24th June, Dr. Lesley Ogilvie, the Hub Secretariat Director took part in the Virtual Dialogue: “Addressing Antimicrobial Resistance for Better Cancer Care – The Important Role of R&D”.
The session, organised by the Union for International Cancer Control (UICC):
・Provided information on various incentives currently being employed to improve the R&D pipeline for novel antimicrobials.
・Highlighted the need to develop a new approach to financing, coordinating, and collaborating on R&D for new antibiotics and diagnostics.
・Explored sustainable pathways for access.
・Highlighted the need for strengthened collaboration towards finding novel solutions and their implementation.
The dialogue featured:
・Per Wahlstedt – Expert, Health and Cancer Care, Swedish Cancer Society (Chair)
・Lesley Ogilvie – Director, Global AMR R&D Hub
・Henry Skinner – Chief Executive Officer, AMR Action Fund
・Margo Warren– Director of Government Engagement and Policy, Access to Medicine Foundation
・Gregory Frank – Director, Global Public Policy, MSD
